解放军医学院学报2023，Vol.44Issue(11)：1280-1285,6.DOI:10.12435/j.issn.2095-5227.2023.084
非小细胞肺癌EGFR-TKIs获得性耐药机制研究进展
Research advances in mechanism of acquired resistance to EGFR-TKIs in non-small cell lung cancer
摘要
Abstract
As the main pathological type of lung cancer,non-small cell lung cancer(NSCLC)accounts for 85%of lung cancer,and threatens human health seriously.The rapid development of epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)has benefited thousands of the patients with NSCLC.Unfortunately,acquired resistance to EGFR TKIs is inevitable,eventually resulting in disease progression,recurrence and death.This review focuses on the latest research advances in the mechanism of acquired resistance to EGFR-TKIs in patients with NSCLC.关键词
非小细胞肺癌/表皮生长因子受体-酪氨酸激酶抑制剂/获得性耐药/肿瘤微环境/铁死亡Key words
non-small cell lung cancer/epidermal growth factor receptor-tyrosine kinase inhibitors/acquired resistance/tumor microenvironment/ferroptosis分类
医药卫生引用本文复制引用
赵燕,胡莹莹..非小细胞肺癌EGFR-TKIs获得性耐药机制研究进展[J].解放军医学院学报,2023,44(11):1280-1285,6.基金项目
广东省医学科学技术研究基金项目(A2021243) （A2021243）
